Eli Lilly partnered with Profluent on April 28, 2026, to develop AI-driven genetic medicines. The collaboration carries a potential total value of $2.25 billion.
Profluent will use its artificial intelligence platform to design advanced gene-editing enzymes. Eli Lilly holds an exclusive license to develop and commercialize the resulting therapies.
The agreement provides Profluent with an upfront payment and research funding. Profluent remains eligible for future milestone payments and sales royalties.